Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications.
Individuals with major mental illness are a high-risk group for cardio-metabolic derangements due to genetic predisposition, developmental and environmental stressors, and lifestyle. This risk is compounded when they receive antipsychotic medications. Guidelines for screening, monitoring, and managing these patients for metabolic problems have been in place for several years. Despite this, recent reports document that this population continues to receive poor care in this regard. In this article, we review the metabolic profile of atypical antipsychotic medications and offer guidelines to reduce the metabolic complications of these agents.
Hasnain
Mehrul
M
Department of Psychiatry, Western Regional Integrated Health Authority, Sir Thomas Roddick Hospital, Stephenville, Newfoundland, Canada. mehrul_hasnain@yahoo.com
Vieweg
W Victor R
WV
Fredrickson
Sonja K
SK
Beatty-Brooks
Mary
M
Fernandez
Antony
A
Pandurangi
Anand K
AK
D014150:Antipsychotic Agents / Q000009:adverse effects*; D002908:Chronic Disease; D016903:Drug Monitoring; D019983:Guideline Adherence; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D001523:Mental Disorders / Q000150:complications / Q000188:drug therapy*; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D011787:Quality of Health Care; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D014150:Antipsychotic Agents